Skip to Main Content
American Flag
JULY 4TH SALE

50% off your first year of Quiver Premium

...

Use Promo Code:

JULY4
American Flag

Merus N.V. Common Shares

MRUS Real Time Price USD
N/A
N/A
N/A
Price Data Unavailable for MRUS
Add to Watchlist
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of MRUS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
MRUS Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
MRUS Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
MRUS Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by MRUS's directors and management

2024Q32024Q42025Q12025Q22025Q3−35k−30k−25k−20k−15k−10k−5k0
Net Shares Purchased by Insiders

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

MRUS Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
MRUS Income Statement
MRUS Balance Sheet
MRUS Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene Mar. 11, 2025
  • Patent Title: Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer Jan. 14, 2025
  • Patent Title: Antibody that binds erbb-2 and erbb-3 Nov. 12, 2024
  • Patent Title: Methods and means for the production of ig-like molecules Oct. 22, 2024
  • Patent Title: Bispecific igg antibodies as t cell engagers Aug. 13, 2024
  • Patent Title: Pd-1 binding domains May. 28, 2024
  • Patent Title: Multivalent antibody Apr. 09, 2024
  • Patent Title: Binding molecules that inhibit cancer growth Mar. 26, 2024
  • Patent Title: Methods and means for the production of ig-like molecules Mar. 12, 2024
  • Patent Title: Antibody producing non-human animals Mar. 12, 2024
  • Patent Title: Clec12axcd3 bispecific antibodies and methods for the treatment of disease Jan. 16, 2024
  • Patent Title: Methods of treating a subject having an egfr-positive and/or erbb-3-positive tumor Nov. 21, 2023
  • Patent Title: Antibody producing non-human animals Oct. 17, 2023
  • Patent Title: Human cd3 binding antibody Aug. 29, 2023
  • Patent Title: Antibodies that modulate a biological activity expressed by a cell Aug. 22, 2023
  • Patent Title: Binding molecules that bind cd137 and pd-l1 Jun. 27, 2023
  • Patent Title: Binding molecules that modulate a biological activity expressed by a cell Jun. 06, 2023
  • Patent Title: Antibody producing non-human animals Jan. 24, 2023
  • Patent Title: Antibody producing non-human animals Sep. 20, 2022
  • Patent Title: Generation of binding molecules Aug. 09, 2022
  • Patent Title: Antibody that binds erbb-2 and erbb-3 Mar. 22, 2022
  • Patent Title: Antibody producing non-human animals Feb. 01, 2022
  • Patent Title: Antibody producing non-human mammals Apr. 06, 2021
  • Patent Title: Recombinant production of mixtures of antibodies Mar. 02, 2021
  • Patent Title: Antibodies that bind egfr and erbb3 Nov. 24, 2020
  • Patent Title: Methods and means for the production of ig-like molecules Aug. 25, 2020
  • Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Jun. 02, 2020
  • Patent Title: Generation of binding molecules May. 12, 2020
  • Patent Title: Recombinant production of mixtures of antibodies Dec. 17, 2019
  • Patent Title: Bispecific igg antibodies as t cell engagers Jul. 23, 2019
  • Patent Title: Methods and means for the production of ig-like molecules Jul. 02, 2019
  • Patent Title: Methods and means for the production of ig-like molecules Jun. 25, 2019
  • Patent Title: Human cd3 binding antibody Apr. 23, 2019
  • Patent Title: Antibody producing non-human mammals Apr. 24, 2018
  • Patent Title: Antibody producing non-human mammals Apr. 17, 2018
  • Patent Title: Human cd3 binding antibody Mar. 13, 2018
  • Patent Title: Generation of binding molecules Mar. 06, 2018
  • Patent Title: Antibody producing non-human mammals Sep. 19, 2017
  • Patent Title: Methods and means for the production of ig-like molecules Sep. 12, 2017
  • Patent Title: Method for selecting a single cell expressing a heterogeneous combination of antibodies Aug. 22, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
MRUS News

Recent insights relating to MRUS

New Insider Disclosure: Silverman Peter B. (COO & GC) disclosed 34000 shares sold of $MRUSArticle Thumbnail
Merus N.V. Announces Pricing of $300 Million Public Offering of Common SharesArticle Thumbnail
New Analyst Forecast: $MRUS Given $110.0 Price TargetArticle Thumbnail
$MRUS stock is up 31% today. Here's what we see in our data.Article Thumbnail
Merus N.V. Reports Positive Interim Clinical Data for Petosemtamab in Combination with Pembrolizumab in Head and Neck CancerArticle Thumbnail
Merus N.V. Publishes Mechanism of Action for Petosemtamab Targeting EGFR and LGR5 in Cancer Journal "Cancers"Article Thumbnail
Merus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual MeetingArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 4000 shares sold of $MRUSArticle Thumbnail
Merus N.V. Updates on Petosemtamab Trials and Financial Outlook for 2025 and BeyondArticle Thumbnail
Merus N.V. Receives Second FDA Breakthrough Therapy Designation for Petosemtamab in Head and Neck Cancer TreatmentArticle Thumbnail
Merus N.V. Announces Publication of eNRGy Trial Results for Bizengri® in NEJM, Targeting NRG1 Fusion-Positive CancersArticle Thumbnail
Biohaven Ltd. and Merus N.V. Announce Research Collaboration for Bispecific Antibody Drug Conjugates DevelopmentArticle Thumbnail
Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab for Metastatic Colorectal CancerArticle Thumbnail
Merus N.V. Updates on Petosemtamab Clinical Trials in Head and Neck Squamous Cell Carcinoma and Metastatic Colorectal CancerArticle Thumbnail
Merus N.V. Receives FDA Approval for BIZENGRI®: First Targeted Therapy for NRG1+ Advanced Pancreatic Adenocarcinoma and NSCLCArticle Thumbnail
Merus N.V. Announces Positive Phase 2 Interim Data for Petosemtamab Monotherapy in Second-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 5000 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Silverman Peter B. (COO & GC) disclosed 10000 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Silverman Peter B. (COO & GC) disclosed 62000 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 8300 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 6000 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 115 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Silverman Peter B. (COO & GC) disclosed 22386 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 250 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 575 shares sold of $MRUSArticle Thumbnail
New Insider Disclosure: Shuman Harry (VP Controller, PAO) disclosed 575 shares sold of $MRUSArticle Thumbnail
CNBC Recommendations

Recent picks made for MRUS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MRUS

MRUS Analyst Ratings

MRUS Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
MRUS Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $MRUS stock a Buy, Sell, or Hold?

  • What is the price target for $MRUS stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

MRUS Top Shareholders
Shareholder
Shares Held
MRUS Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $MRUS stock?

  • Who owns the most shares of $MRUS stock?

  • What funds own $MRUS stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

MRUS Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view MRUS Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Bull Case vs Bear Case data is only available to Quiver Premium subscribers.

Back To Top